0

Investor Presentation

July 6, 2016

Innovative Drug Delivery Solutions

1

2

To the extent any statements made in this presentation contain information that is not historical, these statements are

forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and

Section 21E of the Securities Exchange Act of 1934, as amended. We have based these forward-looking statements

on our current expectations and projections about future events. Our actual results could differ materially from those

discussed in, or implied by, these forward-looking statements.

Forward-looking statements are identified by words such as "believe," "anticipate," "expect," "intend," "plan," "will,"

"may" and other similar expressions. In addition, any statements that refer to expectations, projections or other

characterizations of future events or circumstances are forward-looking statements. Forward-looking statements

include, but are not necessarily limited to, risks and uncertainties, including the difficulty of predicting U.S. Food and

Drug Administration and Canadian Therapeutic Products Directorate approvals, acceptance and demand for new

pharmaceutical products, the impact of competitive products and pricing, new product development and launch,

reliance on key strategic alliances, availability of raw materials and finished products, the regulatory environment, tax

rate assumptions, the outcome of legal proceedings, fluctuations in operating results and other risks detailed from

time to time in the Company's filings with the Securities and Exchange Commission and the Ontario Securities

Commission. IntelGenx undertakes no obligation to update or revise any forward-looking statement.

1

Forward Looking Statements

2

2

2

Oral Thin Films

Oral Thin Films Provide

Significant Market Opportunities

for Improving Drug Delivery

• IntelGenx CEO co-developer of the

Listerine breath strips

• Oral films ideal for elderly, children,

patients who have difficulty swallowing

traditional tablets

• Quicker action to relieve symptoms

3

3

Strong Demographics for Oral Films

Many patient applications are compatible

with oral film characteristics

• Those who have difficult swallowing large pills:

pediatric, geriatric, or dysphagic

• North Americans over 65 will grow from 54MM to 85MM

over the next 15 years

• Patients who suffer gastrointestinal (GI) side effects

from their medication

• Normal patients who would prefer a more discrete

or pleasant administration of the drug

4

4

Making Approved Drugs Better

Rapidly disintegrating film improving

drug performance and easing administration

without the need for water

Films

VersaFilm™

TabletsControlled-release tablets for oral

absorption over an extended time period

IntelGenx Drug Delivery Technology Platforms

VersaTab™ AdVersa™

5

IndicationPartnering

Availability

Formulation

Development

Pilot

StudyPivotal Study Filing Launch

Films$17B

Migraine – Rizaport TM - Rizatriptan Available ex- ES

Erectile Dysfunction - Tadalafil Available

Opioid Dependence Par

Pharmaceuticals

Schizophrenia - Loxapine Available

Undisclosed Term Sheet

Pain Term Sheet

Central Nervous System (CNS) Term Sheet

CNS - Montelukast Available

Respiratory (Cough & Cold) In Discussion

Cardiovascular In Discussion

Tablets$1.7B

Major Depressive Disorder –

Forfivo XL®

Bupropion

Edgemont

Pharmaceuticals

Available ex-USA

Hypertension - Metoprolol Available

Pain - Dronabinol Available

A Robust Product Pipeline to AddressSignificant Market Opportunities

5

6

Forfivo XL

6

• High dose version of Wellbutrin XL®

• Only approved, once-daily, bupropion

HCl 450mg dose in a single tablet

• Launched commercially October 2013

in partnership with Edgemont

Pharmaceuticals

• Q1 2016 net sales grew 39% compared

to Q1 2015, with net sales at $2.5 million

($4.9 million gross)

First 450mg tablet approved by FDA for major depressive disorder

$0.00

$500.00

$1,000.00

$1,500.00

$2,000.00

$2,500.00

$3,000.00

$3,500.00

1Q15 2Q15 3Q15 4Q15 1Q16

Forfivo XL Net Sales ($,000s)

7

7

For Migraines

Leverages VersaFilm™ Technology

• Co-development partnership with RedHill Biopharma

• European Mktg Approval – November 2015

• Definitive agreement signed July 2016 with

Grupo Juste for Spain & additional territories

• Actively pursuing several opportunities to open new

markets - negotiations with future commercialization

partners ongoing

• Planned USA submission to FDA Q4/2016

• Expected USA launch Q2/2017

8

For Erectile Dysfunction

• The first oral thin film using IntelGenx

proprietary drug delivery technology,

VersaFilm™, for ED

• Containing tadalafil (Cialis® - Eli Lilly),

a major molecule in the ED market

• Demonstrated bioequivalence to Cialis®

• Orally disintegrating films without need

for water provide unprecedented patient

convenience and a discrete dosing

alternative

• 505(b)(2) USA NDA submission in

Q4/2016

• Expected USA launch Q4/2017

8

9

Strategy Update

9

10

Strengthened Management TeamOver 20 Employees, including 7 with Ph.D.’s

Andre Godin, CPA, CA

Executive VP, CFO

• 25+ years biotech/pharma

industry experience

• Member of the Canadian

Chartered Professional

Accountants and the

Canadian Institute of

Chartered Accountants

Nadine Paiement, M. Sc.

VP, Research & Development

• Co-inventor of IntelGenx

Trilayer Technology

• 15 years experience in product

development and technology

transfer

Robert Bechard, M. Sc.

VP, Corporate Development

• 20+ years experience in

biopharmaceutical and

venture capital

• Managing Partner of

Lifescience venture fund at

RBC Capital

• Director on 25 lifescience

boards

Edward Miller, B. Comm

Director, Investor Relations

• 15 years experience in investor

relations

• 10 + years experience in

pharmaceutical / biotech

Horst G. Zerbe, Ph. D.

Chairman, President & CEO

• Co-Founder of Listerine

breath strips

• 30+ years drug delivery /

pharma experience

• Holds over 40 patents in drug

delivery and numerous

scientific publications

10

Dana Matzen, Ph.D.

VP, Business Development

• 15 years experience in

pharmaceutical product

licensing

• Former Director,

BD at Paladin Labs

• Completed 13 transaction,

7 new product launches

John Durham, B. Sc.

VP, Operations

• 20+ years experience in

pharmaceutical

manufacturing, quality

management, product

development

• Held executive positions with

several Canadian and US

companies

11

11

Completion of Constructionof Manufacturing Facility

• 17,000 sq ft facility in Montreal -

construction completed in Q1 2016

• Facility to be fully operational by Q1 2017

• High capacity manufacturing and

packaging equipment

• Lower costs, controls quality

and de-risks investment

for new products

GROSS MARGINS of 40% PLUS

We have built a state-of-the-art

oral film development and manufacturing facility

12

12

We are Now Poised for Success

We are focused on areas where oral films

are particularly well-suited:

Develop and commercialize products that provide tangible patient benefits

leveraging oral films, such as:

• Reduced side effects

• Improved bio-availability

• Response time versus existing drugs

• Lifecycle management

• Repurpose existing drugs for new indications using oral films

• “First-to-file” Generic drugs where high technology barriers to

entry exist in reproducing branded films

13

13

What Makes IntelGenx the Best in Oral Films

1. History

• Dr. Zerbe a pioneer with over 30 plus years in oral films

2. Formulation Team

• Strong in applying biopharmaceutical aspects to formulation development

• Top quality scientists: highly creative, focused on problem solving & innovative approaches

• Experienced in developing films for oral (GI), sublingual & buccal absorption

3. Competitive Manufacturing Capabilities

• First in Canada

• New state-of-the-art manufacturing facility

• Offer one-stop-shopping to our partners with lean operations keeping costs down

• Customized manufacturing equipment

14

Financial Results

14

15

Record Results in 2015 Demonstrates Strong Execution of Strategy

Revenue ($M)

0.820.63

5.1

1.7

0

1

2

3

4

5

6

Q1 2016 Q1 2015 2015 Full Year 2014 Full Year

Revenue

$M

15

16

Net Comprehensive Income & Adjusted EBITDA ($M)

-0.71

-0.38

0.8

-2.2

-0.56

0.05

1.7

-1.6

-2.5

-2

-1.5

-1

-0.5

0

0.5

1

1.5

2

Q1 2016 Q1 2015 2015 Full Year 2014 Full Year

Net Income Adjusted EBITDA

$M

Transforming IntelGenx for a Strong Future

16

17

Conclusion

17

18

18

Solid Platform for Growth

Significant Market Potential

• New manufacturing facility will offer many competitive advantages

• Strengthened management team to accelerate execution of business plan

• Implemented product sourcing strategy to identify high-value product opportunities

• Building strategic partnerships with relevant partners in the pharmaceutical industry

19

19

Thank You

www.IntelGenx.com